Please provide your email address to receive an email when new articles are posted on . Older, fit patients with acute myeloid leukemia who received decitabine had transplant and survival rates ...
MINNEAPOLIS--(BUSINESS WIRE)--Aug. 1, 2006--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that the European Medicines Agency (EMEA) ...
Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results